{
    "id": 18004,
    "fullName": "PIM2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "PIM2 over exp indicates an over expression of the Pim2 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 11040,
        "geneSymbol": "PIM2",
        "terms": [
            "PIM2"
        ]
    },
    "variant": "over exp",
    "createDate": "02/15/2016",
    "updateDate": "01/08/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4887,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells over expressing PIM2 were sensitive to TP-3654 both in culture and in human cell line xenograft models, resulting in decreased tumor growth (PMID: 24953177).",
            "molecularProfile": {
                "id": 18333,
                "profileName": "PIM2 over exp"
            },
            "therapy": {
                "id": 3672,
                "therapyName": "TP-3654",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4769,
                    "pubMedId": 24953177,
                    "title": "A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24953177"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4587,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 treatment inhibited proliferation of JAK2 inhibitor-resistant myeloproliferative cancer cell lines harboring JAK2 V617F and elevated protein level of PIM1, PIM2 AND PIM3 in culture (PMID: 26472029).",
            "molecularProfile": {
                "id": 18597,
                "profileName": "JAK2 V617F PIM1 over exp PIM2 over exp PIM3 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 4960,
                "name": "bone marrow cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4621,
                    "pubMedId": 26472029,
                    "title": "The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26472029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7247,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 decreased viability of breast cancer cells with hypoxia-induced increased expression of Pim1 and Pim2 in culture (PMID: 27196781).",
            "molecularProfile": {
                "id": 24804,
                "profileName": "PIM1 over exp PIM2 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6257,
                    "pubMedId": 27196781,
                    "title": "PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196781"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7249,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 decreased viability of colon cancer cells with hypoxia-induced increased expression of Pim1 and Pim2 in culture (PMID: 27196781).",
            "molecularProfile": {
                "id": 24804,
                "profileName": "PIM1 over exp PIM2 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6257,
                    "pubMedId": 27196781,
                    "title": "PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196781"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7245,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a prostate cancer cell line with hypoxia-induced increased expression of Pim1 and Pim2 demonstrated sensitivity to AZD1208 in culture and in xenograft models (PMID: 27196781).",
            "molecularProfile": {
                "id": 24804,
                "profileName": "PIM1 over exp PIM2 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6257,
                    "pubMedId": 27196781,
                    "title": "PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196781"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8920,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim2 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26535,
                "profileName": "PIK3CA H1047R PIM2 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18333,
            "profileName": "PIM2 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 7830,
                    "name": "PIM Inhibitor (Pan)",
                    "profileName": "PIM2 over exp"
                }
            ]
        },
        {
            "id": 18597,
            "profileName": "JAK2 V617F PIM1 over exp PIM2 over exp PIM3 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24804,
            "profileName": "PIM1 over exp PIM2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26535,
            "profileName": "PIK3CA H1047R PIM2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}